<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Xie F</submitter><funding>Research Project of Jiangsu Commission of Health</funding><funding>National Natural Science Foundation of China</funding><funding>Social Development Foundation of Zhenjiang</funding><funding>Natural Science Foundation of Jiangsu Province</funding><pagination>215</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC11806540</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>25(1)</volume><pubmed_abstract>&lt;h4>Background&lt;/h4>The homeobox (HOX) genes especially for HOXA cluster play crucial roles in leukemogenesis. HOXA overexpression caused by genetic alterations, such as KMT2A rearrangements, NUP98- fusions and FLT3-ITD mutations, is frequently identified in AML. However, very few studies determined the DNA methylation-mediated epigenetic regulation of the HOXA cluster genes in AML.&lt;h4>Methods&lt;/h4>We systematically first screened the prognostic value of HOXA cluster genes methylation in AML from The Cancer Genome Atlas (TCGA) datasets. Afterwards, the candidate prognosis-related gene HOXA9 were selected for clinical relevance analysis and were further validated in another independent cohort from our research center.&lt;h4>Results&lt;/h4>The methylation of HOXA9, among HOXA cluster genes, negative</pubmed_abstract><journal>BMC cancer</journal><pubmed_title>Identification of HOXA9 methylation as an epigenetic biomarker predicting prognosis and guiding treatment choice in acute myeloid leukemia.</pubmed_title><pmcid>PMC11806540</pmcid><funding_grant_id>82100183</funding_grant_id><funding_grant_id>M2022123</funding_grant_id><funding_grant_id>SH2023009</funding_grant_id><funding_grant_id>82270179</funding_grant_id><funding_grant_id>BK20221287</funding_grant_id><funding_grant_id>82300164</funding_grant_id><funding_grant_id>BK20230296</funding_grant_id><funding_grant_id>SH2022027</funding_grant_id><pubmed_authors>Qian J</pubmed_authors><pubmed_authors>Xie F</pubmed_authors><pubmed_authors>Zhao YJ</pubmed_authors><pubmed_authors>Wang Y</pubmed_authors><pubmed_authors>Zhou JD</pubmed_authors><pubmed_authors>Zhang XL</pubmed_authors><pubmed_authors>Xu ZJ</pubmed_authors><pubmed_authors>Zhang TJ</pubmed_authors><pubmed_authors>Qiao L</pubmed_authors></additional><is_claimable>false</is_claimable><name>Identification of HOXA9 methylation as an epigenetic biomarker predicting prognosis and guiding treatment choice in acute myeloid leukemia.</name><description>&lt;h4>Background&lt;/h4>The homeobox (HOX) genes especially for HOXA cluster play crucial roles in leukemogenesis. HOXA overexpression caused by genetic alterations, such as KMT2A rearrangements, NUP98- fusions and FLT3-ITD mutations, is frequently identified in AML. However, very few studies determined the DNA methylation-mediated epigenetic regulation of the HOXA cluster genes in AML.&lt;h4>Methods&lt;/h4>We systematically first screened the prognostic value of HOXA cluster genes methylation in AML from The Cancer Genome Atlas (TCGA) datasets. Afterwards, the candidate prognosis-related gene HOXA9 were selected for clinical relevance analysis and were further validated in another independent cohort from our research center.&lt;h4>Results&lt;/h4>The methylation of HOXA9, among HOXA cluster genes, negative</description><dates><release>2025-01-01T00:00:00Z</release><publication>2025 Feb</publication><modification>2025-04-04T01:34:01.225Z</modification><creation>2025-04-04T01:34:01.225Z</creation></dates><accession>S-EPMC11806540</accession><cross_references><pubmed>39920624</pubmed><doi>10.1186/s12885-025-13633-y</doi></cross_references></HashMap>